Alzheimer's disease

BioVie Biomarker Study Points to Improvements in Alzheimer's
BioSpace
Thu, 09/8/22 - 10:42 am
BioVie
biomarkers
Alzheimer's disease
NE3107
Beyond headlines and amyloid, the Alzheimer's pipeline chugs along
Fierce Biotech
Fri, 09/2/22 - 12:59 pm
Alzheimer's disease
clinical trials
drug development
A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity
Fierce Pharma
Mon, 08/29/22 - 10:40 am
Novo Nordisk
semaglutide
NASH
Alzheimer's disease
Saxenda
obesity
AbbVie fends off patent claim in unusual whistleblower case
Fierce Pharma
Fri, 08/26/22 - 12:18 pm
AbbVie
whistleblower lawsuits
whistleblowers
Allergan
Adamas
Alzheimer's disease
Eisai inaugurates new US HQ as closely watched FDA Alzheimer's decision draws near
Fierce Pharma
Sun, 08/21/22 - 09:36 pm
Eisai
headquarters
Alzheimer's disease
FDA
Genuv Cancer Drug Shows Early Potential in Alzheimer's
BioSpace
Thu, 08/18/22 - 11:19 pm
Genuv
Alzheimer's disease
Mekinist
Aduhelm’s loss is a win for value-based drug pricing
MedCity News
Thu, 08/11/22 - 10:39 am
Biogen
Aduhelm
value-based pricing
drug pricing
Alzheimer's disease
Oligomerix receives NIH grant for Phase Ia Alzheimer’s disease study
Clinical Trials Arena
Wed, 08/10/22 - 10:45 am
Oligomerix
NIH
clinical trials
Alzheimer's disease
OLX-07010
Merck is back in Alzheimer's saddle with $1B+ Cerevance pact, years after dropping the BACE
Fierce Biotech
Tue, 08/9/22 - 10:42 am
Merck
Cerevance
Alzheimer's disease
R&D
biobucks
Lilly takes long view on Alzheimer’s drug hopeful as FDA starts expedited review
BioPharma Dive
Fri, 08/5/22 - 10:59 am
Eli Lilly
Alzheimer's disease
FDA
donanemab
Biogen deflects claims it misled shareholders about Aduhelm's success
Fierce Pharma
Mon, 08/1/22 - 10:27 am
Biogen
Aduhelm
Alzheimer's disease
Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say
Reuters
Wed, 07/27/22 - 10:56 am
Cassava Sciences
DOJ
data manipulation
Alzheimer's disease
simufilam
Roche, Biogen temper Alzheimer’s expectations in Q2 calls. Will Lilly follow suit in August?
Fierce Biotech
Fri, 07/22/22 - 11:21 am
Alzheimer's disease
Roche
Biogen
Eli Lilly
lecanemab
gantenerumab
Aduhelm
For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless
Endpoints
Thu, 07/21/22 - 09:47 pm
Biogen
Aduhelm
Alzheimer's disease
SEC
AbbVie dumps Alector's Alzheimer's immunotherapy after phase 1 review
Fierce Biotech
Fri, 07/8/22 - 10:43 am
Alector
AbbVie
Alzheimer's disease
clinical trials
AL003
Biogen-Eisai go for another biomarker approval in Alzheimer's with lecanemab—and snag priority review
Fierce Biotech
Tue, 07/5/22 - 11:58 pm
Biogen
Eisai
FDA
biomarkers
Alzheimer's disease
lecanemab
Fierce NextGen: Despite another key trial failure, Alzheimer's therapy developers find reason for optimism
Fierce Biotech
Wed, 06/29/22 - 10:59 am
Alzheimer's disease
clinical trials
crenezumab
Roche
Genentech
Biogen, citing insurance challenges, shutters one of its Aduhelm studies
BioPharma Dive
Wed, 06/22/22 - 06:54 pm
Biogen
real world data
Alzheimer's disease
Medicare
Aduhelm
Athira Puts Positive Spin on Alzheimer’s Trial Despite Missed Endpoint
BioSpace
Wed, 06/22/22 - 10:28 am
Athira Pharma
fosgonimeton
Alzheimer's disease
clinical trials
Acadia's Alzheimer’s Drug Voted Down by FDA Advisory Committee
BioSpace
Mon, 06/20/22 - 10:30 am
Acadia Pharmaceuticals
Nuplazid
FDA
Alzheimer's disease

Pages